Drugs / GSK4532990
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06613698 | Sep 2024 → Aug 2027 expected | alcoholic liver disease | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 2 | NCT06104319 | Jan 2024 → Sep 2025 | NAFLD1 | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT05583344 | Jan 2023 → Jan 2026 overdue | NAFLD1 | GlaxoSmithKline | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-11-07 | GlaxoSmithKline | Results GSK presents data from its advancing liver pipeline at AASLD 2025 gsk.com ↗
Preliminary findings from the GSK ‘990 STARLIGHT study in alcohol-associated liver disease (ALD), show no emerging safety concerns and demonstrate favourable trends in reduced liver enzyme levels despite ongoing alcohol consumption, that may correspond to improvements in hepatocyte ballooning, a significant indicator of liver injury. |
| 2024-11-13 | GlaxoSmithKline | Results GSK highlights key data from hepatology portfolio at the AASLD’s The Liver Meeting® 2024, emphasising patient impact in areas of high unmet need gsk.com ↗
GSK4532990 HSD17B13 loss-of-function splice variant delays onset of incident metabolic-dysfunction-related and alcohol-related liver disease, slows progression of established liver disease, and lowers risk of liver-related mortality |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-11-07 | GlaxoSmithKline | GSK presents data from its advancing liver pipeline at AASLD 2025 gsk.com ↗ |
| 2024-11-13 | GlaxoSmithKline | GSK highlights key data from hepatology portfolio at the AASLD’s The Liver Meeting® 2024, emphasising patient impact in areas of high unmet need gsk.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK4532990 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05583344 ↗ |